US7002019B2ExpiredUtilityPatentIndex 84
Synthesis of indole thiazole compounds as ligands for the Ah receptor
Est. expiryFeb 12, 2022(expired)· nominal 20-yr term from priority
A61P 35/00A61P 43/00A61P 37/02A61P 3/02A61P 15/00C07D 209/12C07D 413/06C07D 403/06C07D 417/06
84
PatentIndex Score
12
Cited by
1
References
12
Claims
Abstract
A method of synthesizing aromatic ketone compositions of formula I comprising the step of introducing a double bond into the 5 membered ring of the 4,5-dihydro-1,3-azoles moiety of formula II is disclosed. A method of synthesizing aromatic ketone compositions of formula I comprising the step of ring synthesis of the tetrahydro-1,3-azoles of formula XI is also disclosed.
Claims
exact text as granted — not AI-modified1. A method of synthesizing aromatic ketone compositions of formula I:
wherein:
R 1 may be hydrogen or can be selected from the group consisting of (C 1 -C 6 )-alkyl and (C 3 -C 7 )-cycloalkyl, and wherein the alkyl group can be substituted by (C 3 -C 7 )-cycloalkyl or can be mono- or polysubstituted by an aryl group, wherein the aryl group can be mono- or polysubstituted by halogen, (C 1 -C 6 )-alkyl, (C 3 -C 7 )-cycloalkyl, hydroxy and nitro groups;
R 1 may be an aryl group, wherein the aryl group can be mono- or polysubstituted by halogen, (C 1 -C 6 )-alkyl, (C 3 -C 7 )-cycloalkyl, hydroxy and nitro groups;
R 1 may further be a protecting group;
R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 may be the same or different and are each selected from the group consisting of hydrogen, (C 1 -C 6 )-alkyl, (C 3 -C 7 )-cycloalkyl, (C 1 -C 6 )-acyl, (C 1 -C 6 )-alkoxy, alkoxycarbonyl (COOR 1 ), halogen, benzyloxy, the nitro group, the amino group, the (C 1 -C 4 )-mono or dialkyl-substituted amino group, or an aryl group, wherein the aryl group can be mono- or polysubstituted by halogen, (C 1 -C 6 )-alkyl, (C 3 -C 7 )-cycloalkyl, hydroxy and nitro groups;
X and Z may be the same or different and are each selected from the group consisting of O, S and NH;
comprising the step of introducing a double bond into the 5 membered ring of the 4,5-dihydro-1,3-azoles moiety of a compound of the formula II:
wherein the stereochemical centers may have R or S configuration.
2. The method of claim 1 , wherein the step of introducing a double bond comprises oxidation of a compound of the formula II.
3. The method of claim 2 , wherein the oxidation comprises treatment of the selected compound with MnO 2 or NiO 2 .
4. The method of claim 1 , wherein the compound of formula II is prepared by cyclization of the derivatives of the N-substituted indole-3-glyoxylamide of formula III:
where R 8 represents hydrogen or a protecting group.
5. The method of claim 4 , wherein the cyclization comprises treatment with TiCl 4 .
6. The method of claim 1 , wherein the compound of formula II is prepared by cyclization of derivatives of the indole-3-glyoxylates of formula IV:
where Z may be O or S, and R 8 represents hydrogen or the protecting group.
7. The method of claim 4 , wherein the derivatives of the N-substituted indole-3-glyoxylamide of formula III are obtained from derivatives of indole-3-glyoxylic acid of formula V, and the corresponding amines of formula VI:
where Y is selected from amino group, halogen, hydroxyl, alkoxy group (OR 1 ), mercapto group (SH) or alkylthio group (SR 1 ).
8. The method of claim 6 , wherein derivatives of formula IV are obtained from the derivatives of indole-3-glyoxylic acid of formula V, and the corresponding alcohols or thiols of formula VII:
9. A method of synthesizing aromatic ketone compositions of formula I comprising the step of introducing two double bonds into the 5 membered ring of the tetrahydro-1,3-azoles of formula XI:
10. The method of claim 9 , wherein the compound of formula XI is prepared from derivatives of the indole-3-glyoxals of formula X and the corresponding amines of formula VI:
11. The method of claim 1 additionally comprising the step of testing the compound for efficacy as an AHR ligand.
12. The method of claim 9 additionally comprising the step of testing the compound for efficacy as an AHR ligand.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.